“Functional xenon-129 magnetic resonance imaging response to antifibrotic treatment in idiopathic pulmonary fibrosis” Andrew D. Hahn, Katie J. Carey, Gregory P. Barton, Luis A. Torres, Jeff Kammerman, Robert V. Cadman, Kristine E. Lee, Mark L. Schiebler, Nathan Sandbo and Sean B. Fain. ERJ Open Res 2023; 9: 00080-2023.

This article was originally published with an error in the key to figure 1c and d in which “AF” and “No AF” were incorrectly labelled. The corrected figure is shown below. This has also been corrected in the article itself. We apologise for this error.

FIGURE 1.

Plots of a and b) baseline and c and d) change in b and d) red blood cell (RBC)-to-membrane ratio and a and c) ventilation defect percentage (VDP). RBC-to-membrane ratio significantly improved in the antifibrotic (AF) group over 1 year (p=0.002) and increased over that time in 11 out of 12 patients receiving antifibrotic medication. Also shown are images of f) RBC-to-membrane ratio and e) ventilation from an idiopathic pulmonary fibrosis (IPF) patient not taking antifibrotic medication (no-AF) (male, age 65 years) and an IPF patient treated with antifibrotics (male, age 60 years) at baseline and after 1 year. e) VDP is higher in the no-AF case relative to the patient treated with antifibrotic medication. f) RBC-to-membrane ratio appears to decrease over time in the no-AF patient, and recovers in the patient taking antifibrotics. LVP: low ventilation percentage; MVP: medium ventilation percentage; HVP: high ventilation percentage.